Skip to main content

Kaposi Sarcoma

Alyssa Miceli, DO and Jenifer R. Lloyd, DO, FAAD Reviewed 06/2019
 


BASICS

Kaposi sarcoma (KS) was originally described in 1872 by a Hungarian dermatologist named Moritz Kaposi. 

DESCRIPTION

  • Synonym(s): KS; multiple idiopathic hemangiosarcoma

  • KS is a low-grade vascular t...

DIAGNOSIS

HISTORY

  • Cutaneous involvement is most common.

  • Other possible presentations include mucosal and visceral involvement and tumor-associated lymphedema with lower extremity and/or facial swelling.

  • ...

TREATMENT

The major goals of treatment are symptom palliation, prevention of disease progression, and shrinkage of tumor to alleviate edema, organ compromise, and psychological stress. 

GENERAL MEASURES

ONGOING CARE

FOLLOW-UP RECOMMENDATIONS

Patient Monitoring

  • In HIV patients with KS, other opportunistic infections must be treated aggressively.

  • Because non–AIDS-defining malignancies are becoming more co...

REFERENCES

1
Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, et al. Management of AIDS-related Kaposi’s sarcoma. Lancet Oncol.  2007;8(2):167–176. [View Abstract on OvidMedline]
2
Piccolo V, Russ...

ADDITIONAL READING

  • Anglemyer A, Agrawal AK, Rutherford GW. Treatment of Kaposi sarcoma in children with HIV-1 infection. Cochrane Database Syst Rev.  2014;(1):CD009826. [View Abstract on OvidMedl...

CODES

ICD10

  • C46.9 Kaposi’s sarcoma, unspecified

  • C46.3 Kaposi’s sarcoma of lymph nodes

  • C46.0 Kaposi’s sarcoma of skin

  • B20 Human immunodeficiency virus [HIV] disease

  • C46.51 Kaposi’s sarcoma of right lung

  • C46....

CLINICAL PEARLS

  • HHV-8 (also known as KSHV) is the etiologic agent of KS.

  • HHV-8, immunocompromised status, and cytokine-induced growth represent preconditions for the development of KS.

  • HAART is recommen...

Subscribe to Access Full Content

Sign Up for a 10-Day Free Trial

Sign up for a 10-day FREE Trial now and receive full access to all content.

 
×